Early investors in founders building at the frontier of strategic biology.
Cavano Capital’s portfolio spans therapeutics, cell and gene platforms, microbiome science and bio‑manufacturing infrastructure across the globe. Several companies remain in stealth until key clinical or regulatory events are completed.
Develops anti‑PACAP biologics for migraine prevention.
Advances TCR‑based cell therapies, including SCG101 and SCG142.
Builds models that make human microbiology computable.
A Copenhagen spin‑out from a legacy pharmaceutical group with breakthrough oncology IP was stuck in a 24‑month queue for EU first‑in‑human slots, leaving a high‑value asset under‑advanced and under‑valued relative to faster competitors.
Cavano Capital led the seed round, backing a Singapore‑anchored Phase I strategy, structured to meet both HSA and EMA expectations. Working with management and specialist CROs, we helped the company secure earlier first‑in‑human capacity, design a trial acceptable to both regulators and sequence capital around those milestones.
The company generated safe human data around 12 months ahead of regional peers and raised a stepped‑up follow‑on round from specialist oncology investors.
A stealth synthetic biology platform targeting Singapore’s “30 by 30” goals needed to validate production and secure early demand figures without exposing its core IP.
Cavano Capital anchored the pre‑seed round and worked with the founders to structure IP access and a staged data‑room. We helped assemble advisors, sequence conversations with early institutional and public‑sector buyers and shape offtake discussions around defensible milestones.
The company secured strategic offtake commitments alongside its first institutional round, gaining line of sight on revenue while keeping its underlying platform in stealth.
A late-stage orphan drug programme targeting a rare metabolic disorder sat trapped inside a large Danish pharma entity with neither governance nor capital aligned for focused development.
Cavano Capital originated and led the carve‑out, working with the parent company and counsel to transfer IP cleanly and spin the asset into a focused biotech company. We helped recruit a dual‑continent leadership team and structured an ownership model that could attract specialist orphan‑drug investors.
The restructured cap table supported a high‑conviction seed syndicate of specialist orphan‑drug investors, and the company is now advancing through its next clinical and regulatory milestones with a dedicated board.
A high‑efficacy platform developed in Germany hit a COGS barrier that made commercialisation and reimbursement non‑viable.
Cavano Capital joined the syndicate with a thesis around ASEAN manufacturing economics. We backed management’s decision to re‑design the supply chain, brought in Singapore and regional biomanufacturing partners and funded a COGS‑reducing transition.
By relocating key steps into Singapore’s biomanufacturing zones and regional capacity, the company reduced production costs by more than 60% and progressed to a Series A at an improved valuation with clear payer interest.